Macugen three-year safety

Article

Pegaptanib sodium therapy is safe in patients with neovascular age-related macular degeneration (NV-AMD) up to three years, according to study results published in the December issue of the British Journal of Ophthalmology.

Pegaptanib sodium therapy (Macugen) is safe in patients with neovascular age-related macular degeneration (NV-AMD) up to three years, according to study results published in the December issue of the British Journal of Ophthalmology.

Dr Lawrence J. Singerman of the Retina Associates of Cleveland, Ohio, US and colleagues conducted two concurrent prospective, multicentre, double-masked randomized studies of NV-AMD patients treated intravitreally with either pegaptanib sodium (0.3, 1 or 3 mg) or a sham injection every six weeks for 54 weeks, after which subjects discontinued treatment or were randomized for a further 48 weeks of treatment. At week 102, patients receiving the two lower doses of pegaptanib in either of the earlier treatment periods continued; patients from the 3 mg pegaptanib and sham groups were randomized to either 0.3 or 1 mg of pegaptanib.

Pegaptanib was well-tolerated, with mild, transient adverse events related to injection and very few serious adverse events. Pegaptanib was not found to influence electrocardiogram results, and no adverse events related to inhibition of vascular endothelial growth factor were recorded.

Thus the study concluded that pegaptanib was a safe treatment at three years, with limited and usually mild adverse events.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.